VRDN insider trading
NasdaqCM HealthcareViridian Therapeutics, Inc.\DE: insider trade history from SEC Form 4 filings.
About Viridian Therapeutics, Inc.\DE
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
Company website: www.viridiantherapeutics.com
VRDN insider activity at a glance
FilingIQ tracks 82 insider transactions for VRDN in filings since Sep 23, 2021. The most recent transaction is dated Aug 19, 2026.
Across the full history, 11 open-market purchases
and 32 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on VRDN insider trades is 58.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest VRDN Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for VRDN?
- FilingIQ tracks 82 Form 4 insider transactions for VRDN (Viridian Therapeutics, Inc.\DE), covering filings from Sep 23, 2021 onwards. 4 of those are dated within the last 90 days.
- Are VRDN insiders net buyers or net sellers?
- Across the full Form 4 history for VRDN, 11 transactions (13%) were open-market purchases and 32 (39%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does VRDN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is VRDN in?
- Viridian Therapeutics, Inc.\DE (VRDN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.76B.
Methodology & sources
Every VRDN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.